This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Oxothiazolidinecarboxylic acid
- DrugBank Accession Number
- DB12224
- Background
Procysteine has been used in trials studying the treatment of HIV Infections.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Oxothiazolidinecarboxylic acid (DB12224)
- Weight
- Average: 147.15
Monoisotopic: 146.999014199 - Chemical Formula
- C4H5NO3S
- Synonyms
- (-)-2-OXO-4-THIAZOLIDINECARBOXYLIC ACID
- (R)-2-OXOTHIAZOLIDINE-4-CARBOXYLIC ACID
- 2-OXO-4-THIAZOLIDINECARBOXYLIC ACID, L-
- 2-OXO-L-THIAZOLIDINE-4-CARBOXYLIC ACID
- 4-THIAZOLIDINECARBOXYLIC ACID, 2-OXO-, (R)-
- L-2-OXO-4-THIAZOLIDINECARBOXYLIC ACI
- L-2-oxothiazolidine-4-carboxylic acid
- Procysteine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acids and derivatives
- Alternative Parents
- Thiazolines / Propargyl-type 1,3-dipolar organic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Aliphatic heteromonocyclic compound / Alpha-amino acid or derivatives / Azacycle / Carbonyl group / Carboxylic acid / Hydrocarbon derivative / Meta-thiazoline / Monocarboxylic acid or derivatives / Organic 1,3-dipolar compound / Organic nitrogen compound
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- X7063P804E
- CAS number
- 19771-63-2
- InChI Key
- BMLMGCPTLHPWPY-REOHCLBHSA-N
- InChI
- InChI=1S/C4H5NO3S/c6-3(7)2-1-9-4(8)5-2/h2H,1H2,(H,5,8)(H,6,7)/t2-/m0/s1
- IUPAC Name
- (4R)-2-oxo-1,3-thiazolidine-4-carboxylic acid
- SMILES
- OC(=O)[C@@H]1CSC(=O)N1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 72390
- PubChem Substance
- 347828503
- ChemSpider
- 65323
- BindingDB
- 50357221
- 1926836
- ChEBI
- 125673
- ChEMBL
- CHEMBL442218
- ZINC
- ZINC000003787577
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Completed Treatment Human Immunodeficiency Virus (HIV) Infections 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 44.3 mg/mL ALOGPS logP -0.77 ALOGPS logP -0.17 Chemaxon logS -0.52 ALOGPS pKa (Strongest Acidic) 3.19 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 66.4 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 31.35 m3·mol-1 Chemaxon Polarizability 12.45 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 126.01491 predictedDeepCCS 1.0 (2019) [M+H]+ 129.34688 predictedDeepCCS 1.0 (2019) [M+Na]+ 138.31993 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 21:40 / Updated at July 18, 2023 22:57